BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

BioProtect

Status: Completed

Conditions: Prostate Cancer

Treatments: Other: Control; Device: balloon

Study type: Interventional

Funder types: Industry

Identifiers

NCT03400150

BP-007

Details and patient eligibility

About

The BioProtect Balloon Implant™ System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the balloon to reduce the radiation dose delivered to the anterior rectum. The balloon composed of a biodegradable material that maintains that space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.

Full description

This study will be a prospective, multi-center, randomized, double-arm, single blind, concurrently controlled study to assess the safety and efficacy of the balloon in prostate cancer subjects undergoing radiotherapy by means of intensity modulation radiation therapy (IMRT).

Enrollment: 222 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Be at least 18 years of age
• Have been histologically diagnosed with invasive adenocarcinoma of the prostate, at clinical stage T1-T3 (as determined by a biopsy taken within 9 months of the screening visit)
• Be scheduled for radiation therapy (XRT) by means of IMRT

Exclusion criteria

• Any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject has been disease free for a minimum of 5 years
• Prior radical prostatectomy
• Prior cryosurgery or radiotherapy for prostate cancer, or other local therapy for prostate cancer
• Prior radiotherapy to the pelvis, including brachytherapy
• History of prior surgery involving the rectum or anus
• Prior surgical procedure involving the peri-rectal and/or peri-prostatic area

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

222 participants in 2 patient groups

balloon group

Experimental group

Description:

Marking + balloon implantation + IMRT

Treatment:

Device: balloon

Control group

Sham Comparator group

Description:

Marking + IMRT

Treatment:

Other: Control